MedPath

Telemonitoring and E-Coaching in Hypertension

Not Applicable
Recruiting
Conditions
Hypertension
Interventions
Other: Standard care
Other: Home blood pressure monitoring (telemonitoring)
Registration Number
NCT05660226
Lead Sponsor
Maasstad Hospital
Brief Summary

Rationale: Hypertension is the most significant risk factor for cardiovascular disease and can be mitigated by lifestyle and medical management. Telemonitoring as a novel management approach to perform hypertension management at distance has been thriving but became indispensable during the COVID-19 pandemic. However, evidence of an effective implementation for telemonitoring remains to be elucidated.

Hypothesis: Telemonitoring with a smartphone application, which includes mixed automated services for a personal counselling program (PCP), on top of self-monitoring (SM) will lead to improvement of hypertension control rates, medication adherence and lifestyle behaviors and lower health care costs in patients with hypertension when compared to usual care.

Objective: To investigate the effects of PCP+SM on hypertension control rate and lifestyle behaviors as compared with usual care.

Study design: The study is a non-blinded randomized controlled clinical trial in adults with hypertension, in a multicenter hospital setting . We will randomize participants in a 1:1 fashion to the intervention group (PCP+SM), or to the control group (usual care).

Study population: 400 patients, patients, aged ≥18 years with hypertension (RR \>140/90) Main study outcome: hypertension control rate (%\<140/90mmHg) after 6 months (as measured by the SPRINT protocol)

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
400
Inclusion Criteria
  • Age ≥18 years
  • Hypertension (>140/90)
  • Have and use a smartphone or a partner/caregiver who is able to provide the necessary technical support
  • Able to provide written informed consent prior to participation in the study
Exclusion Criteria
  • Current user of a blood pressure monitor apporoved by the Dutch Heart foundation in combination with the Luscii app
  • Persistent atrial fibrillation as indicated in the electronic health record (EHR)
  • Pregnant or planning to become pregnant during the study period
  • Severe kidney disease, defined as estimated glomerular filtration rate <30 per 1.73 m2 or currently on renal replacement therapy (i.e. hemodialysis or peritoneal dialysis)
  • Unable to communicate (not language specific)
  • Recent cardiovascular event (ischemic stroke, transient ischemic attack, myocardial infarction, coronary artery bypass grafting) in the past 3 months
  • Diagnosis of dementia, psychosis as indicated in the electronic health record
  • Life expectancy <1 year, for instance in terminal cancer or NYHA III or IV heart failure
  • Individuals requiring BP monitor cuff size larger than 42cm
  • Patients with proven secondary cause of hypertension for which drug treatment is not first choice (e.g. excessive licorice use, proven renal artery stenosis etc)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlStandard careStandard care in patients with hypertension
InterventionHome blood pressure monitoring (telemonitoring)Home blood pressure monitoring + E-coaching
Primary Outcome Measures
NameTimeMethod
Hypertension control rate6 months

Percentage of patients with blood pressure on target (RR\<135/85)

Secondary Outcome Measures
NameTimeMethod
Self-managementbaseline and 6 months

Self-efficacy to monitor blood pressure, effect of coaching on disease insight and skills using PAM 13 and EQ5DL questionnaires

Hospitalizations6 months and 12 months

Hospitalizations resulting from poor blood pressure control or cardiovascular complications resulting from poor blood pressure control (hypertensive emergencies, MI's, stroke)

Adverse cardiovascular events6 months and 12 months

Myocardial infarction, cerebrovascular events and hypertensive emergencies.

Hypertension control rate6 weeks and 12 months

Percentage of patients with blood pressure on target (RR\<140/90)

Direct Non-Medical Costs6 weeks, 6 months and 12 months

* Training costs related to the use of HBPT for both telenurses, nurse specialists and clinicians

* Development and exploitation costs (time spent developing the HBPT protocol, license costs for the application)

* Salaries for involved health care providers during HBPT

Medication use6 weeks, 6 months and 12 months

Biochemical assessment of antihypertensive medication concentrations in blood. Number of antihypertensive agents used at 6 months. Number of antihypertensive medication changes at 6 months.

Blood pressure control6 weeks, 6 months and 12 months

Mean systolic and diastolic blood pressures for both groups

Patient and Healthcare provider Satisfaction6 months and 12 months

Patients and health-care provider satisfaction as measured with TUQ and MAUQ questionnaires. The scales are from 1 to 7 (disagree to agree)

Indirect Non-Medical costs6 weeks, 6 months and 12 months

* Costs related to work absence (loss of productivity for short-term absence, friction cost for long-term absence)

* Costs related to the hospital visit (travel costs, parking costs)

Indirect medical costs6 weeks, 6 months and 12 months

o Future unrelated medical costs (as calculated using the iMTA PAID module: costs related to other diseases due to improved life expectancy

Direct Medical Costs6 weeks, 6 months and 12 months

* Costs related to HBPT (blood pressure monitor costs)

* Costs related to additional prescribing of antihypertensive drugs

* Costs related to a physical appointment for patients in a hypertension care pathway

* Costs related to reimbursement for patients in a HBPT program

* Costs related to hospital admissions resulting primarily from poorly controlled hypertension or hypertensive emergencies.

* Costs related to hospital admissions or required care pathways following a cardiovascular complication as a result from poorly controlled hypertension

* Future related medical costs

Trial Locations

Locations (1)

Maasstad Ziekenhuis

🇳🇱

Rotterdam, Zuid-Holland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath